{"preliminary_commentary":{"by_channel":{"x_thread":6,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04380636\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pembrolizumab","olaparib"],["pembrolizumab"]],"indication":"unresectable stage III non-small cell lung cancer","name":"KEYLYNK-012","nct_id":"NCT04380636","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keylynk-012-nct04380636. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gray (Gy) over 6 weeks) followed by pembrolizumab plus olaparib placebo twice a day (BID) for approximately 1 year.","label":"pembrolizumab+chemoradiation→pembrolizumab+olaparib placebo","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab 200 mg IV Q3W in combination with 3 cycles of the investigator's choice of platinum doublet chemotherapy and concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by pembrolizumab plus olaparib 300 mg BID for approximately 1 year.","label":"pembrolizumab+chemoradiation→pembrolizumab+olaparib","type":"EXPERIMENTAL"},{"description":"Participants will receive 3 cycles of the investigator's choice of platinum doublet chemotherapy with concurrent standard thoracic radiotherapy (60 Gy over 6 weeks) followed by durvalumab 10 mg/kg every 2 weeks (Q2W) for approximately 1 year.","label":"chemoradiation→durvalumab","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-07-06","type":"ESTIMATED"},"conditions":["Lung Neoplasms","Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":870,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["KEYTRUDA®","MK-3475"],"type":"BIOLOGICAL"},{"name":"Olaparib","otherNames":["LYNPARZA®","MK-7339","AZD2281","KU-0059436"],"type":"DRUG"},{"name":"Placebo for olaparib","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":["VEPESID®"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["PARAPLATIN®"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["PLATINOL®"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["TAXOL®"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":["ALIMTA®"],"type":"DRUG"},{"name":"Thoracic Radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"Durvalumab","otherNames":["IMFINZI®"],"type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-05-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 48 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 72 months"}],"references":[{"citation":"Jabbour SK, Cho BC, Bria E, Kato T, Bhosle J, Gainor JF, Reguart N, Wang L, Morgensztern D, Shentu Y, Kim SJ, Souza F, Reck M. Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 Sep;23(6):e342-e346. doi: 10.1016/j.cllc.2022.04.003. Epub 2022 Apr 29.","pmid":"35618629","type":"DERIVED"}],"start_date":{"date":"2020-07-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","url":"https://clinicaltrials.gov/study/NCT04380636"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keylynk-012-nct04380636"}